Company / R&D per Share
Immunovant, Inc. R&D per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.38
FY2024
5-year range
$0.78 / $2.38
FY2020-FY2024
Trend
+54.4%
vs FY2023
Sector context
#90 of 207
Health Care
What the data says
At $2.38, Immunovant, Inc.'s r&d per share ranks #90 of 207 in the Health Care sector. R&D per Share has increased for 4 consecutive years, from $0.78 in FY2020 to $2.38 in FY2024.
Based on SEC 10-K filings.
2.38 in FY2024 with a 5-year CAGR of +16.5%.
Improved from $1.30 to $2.38 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +36.9%
- 5-Year CAGR
- +16.5%
- 10-Year CAGR
- -
Sector benchmark
#90 of 207 in Health CareTop 43% of 207This company $2.38 Sector average $12.26
▼
-80.6% below sector average
Key checks
Key Insights
- Immunovant, Inc.'s r&d per share has grown for 4 consecutive years.
- In FY2024, r&d per share increased 54.4% year-over-year.
- Ranks #90 out of 207 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.38 | +54.4% |
| FY2023 | $1.54 | +18.4% |
| FY2022 | $1.30 | +40.3% |
| FY2021 | $0.93 | +18.7% |
| FY2020 | $0.78 | -29.5% |
| FY2019 | $1.11 | -4.4% |
| FY2018 | $1.16 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026